Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Cardiff Oncology, Inc.”

3 pharma patents match "Cardiff Oncology, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 3
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 3 pharmaceutical patents matching "Cardiff Oncology, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

3 results for “Cardiff Oncology, Inc.” · 30,257 patents in full index Clear search

  1. US 12263173

    PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

    Cardiff Oncology, Inc. · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  2. US 12144813

    PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

    Cardiff Oncology, Inc. · Granted Nov 19, 2024 · Expires Nov 14, 2044

    granted
  3. US 11957677

    Cancer treatment using FGFR inhibitors and PLK1 inhibitors

    Cardiff Oncology, Inc. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted